MK-2828 Clinical Trials (2026): 4 Studies for Healthy & Chronic Kidney Failure
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 MK-2828 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Healthy & Chronic Kidney Failure) and 134 total planned enrollment. Most recent activity: NCT07348237 (Sep 2026).
MK-2828 clinical trials at a glance: phase × recruitment status
| Phase | completed | Total |
|---|---|---|
| P1 | 4 | 4 |
MK-2828 clinical trials by indication
Healthy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07435194 | MK-2828-007 | P1 | completed | A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) |
| NCT07431866 | MK-2828-005 | P1 | completed | A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) |
Chronic Kidney Failure (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07348237 | MK-2828-006 | P1 | completed | A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) |
Diabetes Mellitus, Type 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07089784 | MK-2828-003 | P1 | completed | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) |
All MK-2828 trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07348237 | MK-2828-006 | A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) | P1 | completed | 18 | Merck Sharp & Dohme LLC | Mar 2026 |
| NCT07435194 | MK-2828-007 | A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007) | P1 | completed | 29 | Merck Sharp & Dohme LLC | Mar 2026 |
| NCT07431866 | MK-2828-005 | A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005) | P1 | completed | 41 | Merck Sharp & Dohme LLC | Mar 2026 |
| NCT07089784 | MK-2828-003 | Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | P1 | completed | 46 | Merck Sharp & Dohme LLC | Sep 2025 |
MK-2828 clinical trials: frequently asked questions
- How many MK-2828 clinical trials are there?
- 4 MK-2828 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are marked completed.
- Are MK-2828 clinical trials recruiting in 2026?
- No active MK-2828 trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is MK-2828 being studied for?
- MK-2828 is being studied for Healthy, Chronic Kidney Failure, Diabetes Mellitus, Type 2, End-Stage Renal Disease, Renal Impairment. The trials are grouped by indication on this page.
- What phase is MK-2828 in?
- MK-2828 clinical trials span 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors MK-2828 clinical trials?
- The lead sponsor across the most MK-2828 trials is Merck Sharp & Dohme LLC. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming MK-2828as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: